FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Santa Rosa Press Democrat8h
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
California Made a Big Bet on Producing Its Own Insulin, But There’s No ‘Date Certain’ for Delivery
During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...
CA insulin
Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...
Medical Xpress12d
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj ... Both a 3-mL ...
Saudi Gazette on MSN12d
Saudi Arabia inaugurates first local insulin manufacturing facility, advancing healthcare self-sufficiency
In a landmark moment for Saudi Arabia’s healthcare sector, the Kingdom inaugurated its first local insulin manufacturing ...
Pharm Exec14d
FDA Approves Sanofi’s Rapid Acting Insulin Biosimilar Merilog for Diabetes
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for improving glycemic control ...
Medscape14d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
BioSpace14d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.
Medscape13d
Despite Price Caps, Some Still Struggle to Access Insulin
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...